The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong
|ClinicalTrials.gov Identifier: NCT01628289|
Recruitment Status : Completed
First Posted : June 26, 2012
Last Update Posted : June 26, 2012
Introduction: There is no debate that people with diabetes should be screened for the development of retinopathy which can threaten their sight. However, there is no routine screening for retinopathy in Hong Kong at present. Many overseas countries find that they miss a large proportion of their target population and, with reliance on co-payments for screening, as is the case with the limited opportunistic screening at present, the cost-effectiveness of any routine service in Hong Kong could be reduced as is predicted by Hart's inverse care law.
Aim: This study will determine the potential cost-effectiveness of screening for retinopathy in Hong Kong under a free system and one in which a co-payment is charged.
Methods: Primary care patients attending General Outpatient Clinics on Hong Kong Island for their routine diabetic care will randomly be offered screening either at no charge or with the normal co-payment of $65. Those who are willing and unwilling to be screened will be compared for their clinical, lifestyle and socioeconomic characteristics and those unwilling will be asked their reasons. The uptake of screening at no fee and with a payment will be compared as will the prevalence of retinopathy in the two fee groups. Subsequent screening at one year will be offered at the same fee and uptake again compared.
The principal analyses will (a) identify the characteristics of those willing to be screened and reasons for not being screened (b) the uptake of screening when a co-payment is charged compared to when it is free (c) whether there is a difference in the prevalence of retinopathy between the group willing to pay and those who accept free screening and (d) the uptake of re-screening in year 2.
The resulting cost-effectiveness model will use these data, the cost data collected during the study and overseas data on benefits of treatment to model the cost-effectiveness of screening for retinopathy in Hong Kong if it were to be offered free or with a co-payment. This information will be important to determine the most cost-effective means of implementing this preventative strategy to preserve sight and quality of life.
|Condition or disease||Intervention/treatment|
|Diabetic Retinopathy||Other: charging a co-payment for Diabetic Retinopathy screening Other: free screening without charging a co-payment|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4644 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Primary Purpose:||Health Services Research|
|Official Title:||The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong|
|Study Start Date :||February 2009|
|Primary Completion Date :||August 2009|
|Study Completion Date :||August 2010|
free screening group
Subjects in this group receive free diabetic retinopathy screening.
Other: free screening without charging a co-payment
The intervention is to provide free screening without charging a co-payment
Pay screening group
Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
Other: charging a co-payment for Diabetic Retinopathy screening
The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
- Retinopathy profile in the two groups [ Time Frame: the first year ]The extent of diabetic retinopathy in two groups were measured in the first year screening.
- Subjects' attendance of the screening [ Time Frame: the first year ]Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the first year screening.
- Retinopathy profile in the two groups [ Time Frame: the second year ]The extent of diabetic retinopathy in two groups were measured in the second year screening.
- Subjects' attendance of the screening [ Time Frame: the second year ]Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the second year screening.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628289
|Aberdeen General Outpatient Clinic,Hospital Authority|
|Hong Kong, China|
|Department of Community Medicine,The University of Hong Kong|
|Hong Kong, China|
|Eye Institute, Faculty of Medicine, The University of Hong Kong, Hong Kong|
|Hong Kong, China|
|Principal Investigator:||Sarah M McGhee, PhD||The University of Hong Kong|